










































Increase in NF-kappaB binding affinity of the variant C allele of
the toll-like receptor 9 -1237T/C polymorphism is associated with
Helicobacter pylori-induced gastric disease
Citation for published version:
Ng, MTH, Van't Hof, R, Crockett, JC, Hope, ME, Berry, S, Thomson, J, McLean, MH, McColl, KEL, El-Omar,
EM & Hold, GL 2010, 'Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9
-1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease' Infection and
Immunity, vol. 78, no. 3, pp. 1345-52. DOI: 10.1128/IAI.01226-09
Digital Object Identifier (DOI):
10.1128/IAI.01226-09
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
INFECTION AND IMMUNITY, Mar. 2010, p. 1345–1352 Vol. 78, No. 3
0019-9567/10/$12.00 doi:10.1128/IAI.01226-09
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Increase in NF-B Binding Affinity of the Variant C Allele of the
Toll-Like Receptor 9 1237T/C Polymorphism Is Associated
with Helicobacter pylori-Induced Gastric Disease
Mike Tsz Hin Ng,1 Rob van’t Hof,2 Julie C. Crockett,1 Mairi E. Hope,1 Susan Berry,1 John Thomson,1
Mairi H. McLean,1 Kenneth E. L. McColl,3 Emad M. El-Omar,1 and Georgina L. Hold1*
Division of Applied Medicine, Aberdeen University, Aberdeen, United Kingdom1; Rheumatic Diseases Unit,
Molecular Medicine Centre, Edinburgh University, Edinburgh, United Kingdom2; and Department of
Medicine and Therapeutics, Glasgow University, Western Infirmary, Glasgow, United Kingdom3
Received 29 October 2009/Returned for modification 1 December 2009/Accepted 18 December 2009
Colonization of the gastric mucosa by Helicobacter pylori can lead to serious clinical outcomes, including
gastric cancer. Toll-like receptors (TLRs) play an important role in the host response to H. pylori through the
recognition of pathogen-associated molecular patterns. TLR9, in particular, is partly responsible for initiating
bacterial induced immunity by binding unmethylated CpG-DNA, which is abundant in bacteria. A well-
documented single nucleotide polymorphism (SNP) within the TLR9 promoter (TLR91237T/C), is associated
with a variety of inflammatory disorders, including allergic asthma, inflammatory bowel disease, and atopy.
Analysis of the TLR9 promoter gene sequence has shown that carriage of the variant “C” allele at position
1237 creates a potential NF-B binding site that would theoretically increase the transcriptional activity of
the gene. In this study, we report that the TLR9 1237 C allele was significantly associated with the
development of H. pylori-induced premalignant gastric changes. Functional analysis of the SNP, supporting the
data generated from the genetic association study, showed that carriage of the C allele increased TLR9
transcriptional activity driven mainly by activation of NF-B. Collectively, these findings confirm that the
TLR9 1237T/C polymorphism is a risk factor for the development of H. pylori-induced premalignant gastric
changes and provide a plausible mechanistic explanation.
Helicobacter pylori infection is associated with a variety of
clinical outcomes including gastric cancer and duodenal ulcer
disease (24, 30, 35). These differing outcomes are defined in
part by changes in gastric acid secretion, which is influenced by
the severity and distribution of H. pylori-induced gastritis. Se-
vere inflammation of the gastric mucosa in the corpus region
can inhibit parietal cells from secreting acid and may eventu-
ally cause gastric atrophy and hypochlorhydria (HC), both of
which are precursors of gastric cancer. On the other hand,
duodenal ulcers are associated with an antral predominant
pattern of gastritis, high acid secretion, and a decreased risk of
gastric cancer (9, 14). The host immune response has a strong
role in defining the outcome of H. pylori infection, and poly-
morphisms in genes that control this immune response have
been shown to influence risk of gastric cancer (6, 7, 23, 25).
More recently, polymorphisms in genes involved in H. pylori
recognition have also been shown to be important (11, 18).
Toll-like receptors (TLRs) are important innate immunity
regulators that can be activated upon recognition of bacterial
and viral ligands known as pathogen-associated molecular pat-
terns (PAMPs). TLR-mediated signaling pathways are primar-
ily NF-B dependent, NF-B being a key transcription factor
in the release and production of proinflammatory mediators,
which have important functions with regard to antigen presen-
tation and controlling the release of antibodies (36). In hu-
mans, 10 different TLRs have been identified; in particular,
TLR9 recognizes unmethylated CpG oligonucleotides that are
abundant in bacterial DNA, with TLR9 expression mainly re-
stricted to plasmacytoid dendritic cells (pDC), monocytes, and
B cells (15, 39). CpG-DNA binds to TLR9 and initiates MyD88
recruitment leading to the phosphorylation of IRAK and
TRAF6 and ultimately NF-B activation (19, 21). PAMP rec-
ognition by TLR9 is distinctive from the other TLRs that
recognize bacterial PAMPs in that recognition takes place on
the surface of the endosomal compartment as opposed to the
cell surface (15). The merit of interlocalization is to allow
TLR9 to interact with pathogens that have previously been
phagocytosed and minimize the chance of the recognition of
self-antigen. Although pDC levels are low in peripheral blood,
their presence is responsible for interleukin-12 (IL-12) and
type I interferon (IFN) production that has implications in the
activation of NK cells and monocytes and in Th-1 cell differ-
entiation (20).
Several single nucleotide polymorphisms (SNPs) have been
identified within the TLR9 gene. The 1237T/C SNP
(rs5743836) is the most reported and has been shown to be
associated with various inflammatory related diseases, includ-
ing allergic asthma and Crohn’s disease (22, 37). In silico anal-
ysis of rs5743836 shows that carriage of the variant “C” allele
creates a putative NF-B binding site (Fig. 1). This extra bind-
ing site was postulated to enhance the transcriptional activa-
tion of TLR9 and potentially affect CpG-DNA-induced activa-
tion of proinflammatory chemokines, cytokines, and the
adaptive immune response (13). However, a recent report ex-
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amining the association of rs5743836 with atopic eczema
showed that the risk allele was the “T” allele. This finding was
published, along with an assessment of promoter activity using
a reporter assay, which indicated that basal promoter activity
was higher in the TT allelic variant sequence than in the CC
allelic variant (29).
Since both H. pylori infection and TLR9-mediated immune
responses are mainly Th-1 phenotype, an increased TLR9 ac-
tivation through carriage of the risk “C” allele could exagger-
ate the subsequent inflammatory response. The aim of the
present study was to determine whether the TLR9 1237T/C
polymorphism is important with respect to the different clinical
outcomes of H. pylori infection and to define the molecular
mechanism involved. In order to assess the changes in tran-
scriptional activity, we designed and used a luciferase reporter
system containing each of the promoter regions from the TLR9
allelic variants. Changes in binding affinity of NF-B to the
TLR9 promoter region were also assessed using Noshift tran-
scriptional factor (DNA-protein interaction) analysis.
MATERIALS AND METHODS
Study populations. To determine whether the TLR91237T/C polymorphism
is associated with differing outcomes of H. pylori infection, we studied a cohort of
168 healthy Caucasian first-degree relatives of gastric cancer patients from the
West of Scotland. These subjects had been extensively investigated in relation to
their H. pylori status (assessed by [14C]urea breath test, serology, rapid slide
urease test, culture, and histology). Their gastric phenotype was defined histo-
logically by assessment of antral and corpus biopsies for H. pylori density, com-
bined inflammatory scores (active and chronic giving a maximum score of 6, with
a range from 0 to 6) and the presence of mucosal atrophy (score of 0 to 3) (31).
In addition, these subjects had their peak acid output measured in response to
pentagastrin stimulation (PAOpg), and the subjects were designated as having
HC if their PAOpg was 15 mmol/h. Corpus atrophy was absent in all subjects
with a PAOpg of 15 mmol/h. The 168 subjects were then classified into three
distinct groups: (i) 51 subjects had H. pylori infection, HC, and gastric atrophy;
(ii) 66 subjects had H. pylori infection but no HC or corpus atrophy; and (iii) 51
subjects had no evidence of H. pylori infection and had normal acid secretion and
gastric morphology. One hundred randomly selected umbilical cord blood DNA
samples from the West of Scotland were used as population controls for the
genetic studies. The institutional review boards of the participating centers ap-
proved the study, and written informed consent was obtained from all subjects.
TLR9 genotyping. All genotyping was performed on genomic DNA extracted
from leukocytes. The TLR9 1237T/C polymorphism (rs5743836) was geno-
typed by using a predesigned Applied Biosystems 5 nuclease SNP genotyping
assay, using minor groove binding probes 5-labeled with VIC or FAM (6-
carboxyfluoresceine) fluorochromes to detect the T or C allele, respectively. For
TLR9 1237T/C, the forward primer 5-CAGAGACATAATGGAGGCAAAG
GA-3 and the reverse primer 5-GCCTTGGGATGTGCTGTTC-3 were used,
along with the wild-type probe VIC (CTGCCTGAAAACT) and the variant
allele probe FAM (TCTGCCTGGAAACT). Allelic discrimination analyses
were prepared by using standard reactions conditions. Real-time and endpoint
analyses were performed by using an ABI Prism 7700 sequence detection system
(PE Applied Biosystems). The results were confirmed by direct sequencing of
selected samples of each genotype. Representative samples from these con-
firmed genotypes were then taken and used for functional assessment of the
polymorphism.
Luciferase reporter assays. TLR9 promoter sequences (1471 to 29) from
subjects homozygous for wild-type (TLR9 1237T/T) or variant (TLR9
1237C/C) genotypes were generated by PCR using the primers TLR9f (5-CT
AGTGGTACCAGCAGGGGAATAAGACGAT-3) and TLR9r (5-CAGGGG
ACTGAGAGCTGTTG-3). PCR cycling conditions to generate TLR9 promoter
sequences were as follows: 94°C for 4 min, followed by 30 cycles of denaturation
at 94°C for 30 s, annealing at 62.4°C for 30 s, and extension at 68°C for 90 s. The
last cycle was followed by an extension step at 68°C for 10 min. The PCR
fragments were inserted into the pGL3-Basic vector (Promega, Madison, MI)
using the KpnI and XhoI restriction sites, generating TLR9-T-Luc and TLR9-
C-Luc. Once the promoter sequences had been successfully incorporated into
the reporter vectors, sequence analysis was used to verify that no PCR or cloning
errors had been introduced.
HEK293 cells (American Type Culture Collection, Middlesex, United King-
dom) were maintained in -MEM growth medium supplemented with 1%
L-glutamine and 10% (vol/vol) fetal calf serum (Sigma Aldrich, Dorset, United
Kingdom), and TLR9-luciferase constructs and an internal control vector —thy-
midine kinase promoter-driven Renilla plasmid (pRL-TK-Renilla)—were tran-
siently transfected by using Fugene-6 (Roche Diagnostics, East Sussex, United
Kingdom) at a ratio of 3:1 (volume [l] Fugene to mass [g] DNA constructs).
After 8 h of incubation at 37°C in 5% CO2, various stimulants (tumor necrosis
factor alpha [TNF-; 0.25 to 0.75 ng/ml]; lipopolysaccharide [LPS] from Salmo-
nella enterica serotype Typhimurium [Sigma commercial preparation L6143], and
H. pylori [ATCC 26695 prepared in-house according to the Westphal method and
subsequent lipoprotein purification by ultracentrifugation] [16, 40] at 100 to 500
ng/ml) and E. coli CpG-DNA (5 g/ml) were added, and the cells were incubated
for a further 16 h. The cell lysates were collected and transferred to 96-well black
wall plates. Dual Luciferase (Stop and Glow; Promega) measurements were
performed by using a luminometric plate reader (Victor3; Wallac, Finland;
BioTek Instruments, Winooski, VT). The effect of each stimulant was assessed in
six independent experiments with quadruplicate samples for each stimulant con-
centration. The results are reported as the fold increase in relative luminescence
in arbitrary units (RLA) of TLR9 compared to the promoterless control vector
pGl3-Basic.
Noshift NF-B transcriptional factor assays. Initial Noshift transcriptional
factor assays were performed using activated HeLa nuclear extracts as positive
control experiments, with subsequent experiments performed using freshly ex-
tracted nuclear proteins from HEK293 cells that had undergone stimulation as
described previously in the reporter assays. Nuclear protein extraction from
HEK293 cells was performed by using a NucBuster nuclear extraction kit ac-
cording to the manufacturer’s protocol (Merck Bioscience, Nottingham, United
Kingdom). Protein concentrations of the nuclear protein extracts were deter-
mined by using the bicinchoninic acid assay (Pierce Biotechnology, Rock-
ford, IL).
Biotinylated oligonucleotide probes (Sigma Aldrich, Dorset, United Kingdom)
for the Noshift assay were designed for the region surrounding the TLR9
1237T/C polymorphism: wild-type sequence 46T, 5-CAAAGGAGGGGTCA
TATGAGACTTGGGGGAGTTTTCAGGCAGAGG-3; and mutant sequence
46C, 5-CAAAGGAGGGGTCATATGAGACTTGGGGGAGTTTCCAGGCA
GAGG-3. An unlabeled copy of the probes was synthesized for competitive
binding studies.
Noshift transcription factor analysis was performed according to the manu-
facturer’s protocol using a mouse anti-human NF-B (p65) monoclonal antibody
(Merck Bioscience, Nottingham, United Kingdom). Competition studies were
performed with either unlabeled competitor DNA supplied in the kit as a stan-
dard, unlabeled 46C, and unlabeled 46T used at a concentration 10 times in
excess of 46C. The absorbance was measured at 450 nm by using a Labsystem
Multiskan photometric plate reader (VWR international, Leicestershire, United
Kingdom).
FIG. 1. Schematic diagram showing transcriptional factors and ac-
tivator binding sites in the TLR9 promoter region. In silico analysis
shows that the C allele at position 1237 creates an extra putative
NF-B binding site.
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Statistical analysis. The effect of the TLR9 1237 T/C polymorphism on acid
secretory status and histological parameters (inflammation and atrophy) was
assessed by using a Mann-Whitney U test with significance taken at the 5% level.
Hardy-Weinberg equilibrium of alleles at individual loci was assessed by 2
statistics. Odds ratios (OR) with Cornfield 95% confidence intervals (CIs) were
computed by logistical regression using STATA software (version 7.0; STATA
Press, College Station, TX). ORs for HC were age adjusted (categorized as 35,
36 to 45, 46 to 55, and	55 years in age) because of its age dependence, and their
CIs were based on robust variance estimates, adjusted for within-family corre-
lation, to account for sampling of several members of a given family.
Luciferase reporter data were calculated as means
 the standard errors of the
mean (SEM) unless otherwise stated. Statistical analysis was performed by using
either Tukey’s post hoc test or an unpaired two-sample t test for equal means
using SPSS software (LEAD Technologies, Chicago, IL). DNA–NF-B interac-
tion results were expressed as means 
 the standard deviations (SD) and ana-
lyzed using t test statistics with SPSS (LEAD Technologies). P values of 0.05
were considered significant.
RESULTS
In the control population, the alleles at the TLR9 1237
locus were in Hardy-Weinberg equilibrium, with nonsignificant
2 values. The frequency of the variant allele in the control
population was 14%, which is similar to those reported from
other Caucasian studies.
Association of TLR9 1237T/C polymorphism with risk of
H. pylori infection and clinical outcome. The TLR9 polymor-
phism was not associated with risk of H. pylori infection. Com-
paring all infected subjects (with or without precancerous ab-
normalities) to uninfected subjects, the adjusted OR for
infection was 1.0 (95% CI  0.43 to 2.2). However, there was
a significantly higher frequency of the variant C allele in H.
pylori-infected subjects with HC and gastric atrophy compared
to infected subjects with neither abnormality. A total of 26
(51%) of the 51 subjects with HC and atrophy were variant
carriers compared to only 14 (21%) of 66 infected subjects
without these precancerous changes. The OR of HC/atrophy
for carriers of the C allele was 3.9 (95% CI  1.7 to 8.6),
adjusted for age and multiple sampling from the same family
(Table 1).
Effect of TLR91237T/C polymorphism on TLR9 transcrip-
tional activity. The results from genotyping analyses indicated
that carriage of the variant “C” allele is a risk factor for de-
velopment of premalignant gastric changes in H. pylori-in-
fected subjects. In silico sequence analysis also indicated that
the presence of the variant “C” allele created an extra putative
NF-B transcriptional binding site (Fig. 1). In order to define
the effect on promoter activity caused by the TLR9 1237T/C
polymorphism, luciferase reporter constructs were generated
that contained either the wild-type (TLR9-T-Luc) or the vari-
ant (TLR9-C-Luc). TLR9 promoter regions were transfected
into HEK293 cells together with a control TK-Renilla reporter
plasmid, and the cells were stimulated with TNF-, LPS, and
CpG-DNA at various concentrations.
The constructs containing the TLR9 promoter region
showed an 3-fold increase (P  0.001) in luciferase activity
compared to the promoter-less pGl3-Basic vector (Fig. 2).
However, the difference in transcriptional activation between
the wild-type and variant constructs under basal conditions was
not statistically significant.
Since the “C” variant of the promoter is predicted to intro-
duce an additional NF-B consensus site, we next studied
promoter activity in response to activators of the NF-B path-
way. A range of concentrations of TNF- were examined for
effectiveness at inducing luciferase expression. After 16 h of
stimulation, 0.5 ng of TNF-/ml was the most effective con-
centration and gave maximal transcriptional activation for both
wild-type and variant TLR9 promoter constructs (data not
shown). TNF- induced a 20% increase in signal for the wild
type (TLR9-T-Luc)-containing vector compared to a 40% in-
crease seen in the variant (TLR9-C-Luc)-containing vector
(P  0.001) (Fig. 3).
The effect of the “C” variant on transcriptional activation
TABLE 1. Genotype frequencies and adjusted odds ratios for the TLR9 1237T/C polymorphism
Subject
genotype
H. pylori-positive subjects H. pylori-negative subjects
Population controls










T/T 25 52 1.0 35 1.0 75
T/C 26 14 3.9 (1.7–8.6) 15 0.9 (0.2–3.8) 22
C/C 0 0 1 3
a The OR (and Cornfield 95% confidence interval) for low-acid versus normal/high-acid conditions, adjusted for age and within-family sampling, is given. ORs were
calculated for the carriage of “C” (TT versus T/C  C/C).
b The OR for H. pylori-positive versus H. pylori-negative subjects is given.
FIG. 2. Basal transcriptional activity of pGl3-Basic and TLR9-T-
Luc or TLR9-C-Luc in HEK293. Control plasmid pRL-TK (Renilla)
was used for transfection efficiency normalization of luciferase activity.
The results are reported as the fold increase in RLA of TLR9 com-
pared to the promoterless control vector pGl3-Basic. The figure shows
the mean 
 the SEM of results obtained from six experiments, each
performed in quadruplicate. The statistical significance of differences
in luciferase activity between TLR9-T-Luc and TLR9-C-Luc was as-
sessed by using Tukey’s post hoc test (, P  0.001).
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was also assessed after stimulation with microbial ligands, in-
cluding LPS derived from S. Typhimurium and H. pylori (both
assessed at between 100 and 500 ng/ml) and CpG-DNA (5 g).
An increase in transcriptional activity was observed with both
S. Typhimurium and H. pylori LPS over the range of concen-
trations (data not shown), with the 200-ng/ml concentration
giving a maximal increase for both LPS formulations. The
pattern of increase in transcriptional activity was similar, with
S. Typhimurium LPS and H. pylori LPS showing 16 and 9%
elevations in transcriptional activity of the wild type (TLR9-T-
Luc)-containing vector compared to a 77 and 53% increase
when the cells were transfected with the variant (TLR9-C-Luc;
P  0.01 for S. Typhimurium LPS and P  0.025 for H. pylori
LPS). CpG-DNA-induced promoter transcriptional activity
was also more significant in cells transfected with the C allelic
variant containing vector (TLR9 1237C) than the wild type
(TLR9-T-Luc) (Fig. 3), with a 31% increase in transcriptional
activity observed (P  0.025). Taken together, these data show
that the presence of the extra putative NF-B binding site
within the C allelic variant promotes TLR9 transcription in
response to various stimuli more effectively than the wild-type
TLR9 1237T sequence.
Comparison of NF-B binding affinity between wild-type
and variant TLR9 1237 promoter sequences. In order to
confirm that NF-B binding was responsible for the increase in
transcriptional activity seen in the variant (TLR9-C-Luc) con-
taining vector, the sequence encompassing the polymorphism
was analyzed for the binding capacity of potential NF-B tran-
scriptional binding sites by using Noshift transcriptional factor
analysis. The interaction between NF-B and both TLR9
1237T and TLR9 1237C allelic variants was assessed ini-
tially using 46-bp biotin-labeled oligonucleotides and HeLa
cell nuclear protein extracts (positive control). The results
showed that NF-B could bind to both wild-type 46T (TLR9
1237T) and variant 46C (TLR9 1237C), but the binding
affinity of variant 46C was significantly higher compared to the
wild-type 46T (unpaired t test; , P  0.01) (Fig. 4). These
findings were further substantiated through competitor studies
using unlabeled wild-type 46T probe (N46T), unlabeled 46C
probe (N46C), and unlabeled positive control standard NF-B
probe (SP), with the inclusion of the unlabeled wild-type
46T probe showing a nonsignificant level of change compared
to the use of 46C alone.
In order to correlate the results obtained from our reporter
assays with our DNA-protein interaction analysis, it was essen-
tial to assess the binding affinity of the variant promoter region
sequence to nuclear protein extracts obtained from HEK293
cells after stimulation with the same stimulants as for the
previously described luciferase reporter assays. A twofold in-
crease in NF-B/DNA interactions was observed when the 46C
probe was incubated with nuclear extracts of nonstimulated
HEK293 cells compared to the 46T probe. The pattern of
NF-B–DNA interaction was similar to that detected previ-
ously using HeLa nuclear protein extracts (data not shown).
This experiment was then repeated with HEK293 nuclear ex-
tracts that had been subjected to stimulation with the various
FIG. 3. Reporter analysis of TLR9 promoter variants in response to various stimulants. HEK293 cells were transiently transfected with
promoterless pGl3-Basic, TLR9-T-Luc, or TLR9-C-Luc. The transfection efficiency was normalized by cotransfection of a pRL-TK Renilla control
plasmid. Cultures were stimulated with, TNF- (0.5 ng/ml), serovar Typhimurium and H. pylori LPS (200 ng/ml) or CpG-DNA (5 g/ml) for 16 h
before the cells were lysed for luciferase measurements. The results are reported as the fold increase in RLA of the TLR9 constructs compared
to the promoterless pGl3-Basic vector. The data represent the mean
 the SEM of six experiments each performed in quadruplicate. The statistical
significance of differences in luciferase activity between TLR9-T-Luc and TLR9-C-Luc was assessed by using the Student t test (unpaired) (*, P 
0.001, **, P  0.025, ***, P  0.01).
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stimulants used in the reporter assays. The increase in NF-B
after stimulation was calculated relative to the increase seen
with nuclear protein extracts of unstimulated HEK293 cells.
An increase in nuclear NF-B was detected with TNF-, LPS
from S. Typhimurium and H. pylori, and CpG-DNA (Fig. 5).
The maximal increase in nuclear NF-B varied according to
the stimulant and also occurred in a time-dependent manner
(data not shown), with TNF-- and LPS-stimulated extracts
showing maximal increases within 30 min compared to CpG-
DNA stimulation, whose maximal increase was detected at
8.5 h (Fig. 5).
DISCUSSION
Toll receptors play a crucial role within the innate immune
system. In the case of TLR9, its role is primarily associated
with the maturation of dendritic cells and the release of proin-
flammatory cytokines via activation of NF-B (19). The TLR9
gene, although highly conserved across species, has distinct
sequence variations between hosts that in turn elicit different
responses to CpG motifs. These variations may partly explain
how genetic polymorphisms in TLR9 play a role in disease risk.
Interestingly, however, few studies to date have shown a pos-
itive correlation between SNPs in TLR9 and disease suscepti-
bility (8).
Of the four common TLR9 SNPs, the 1237T/C promoter
polymorphism has been the most evaluated for association
with various diseases (13, 22, 28, 29, 37). Lazarus et al. per-
formed a case control study reporting that the C allele was a
risk factor for asthma but with only marginal statistical signif-
icance (22). In contrast, Novak et al. suggested that the T allele
was associated with increased risk of atopic eczema (29). Since
evidence already existed to indicate that carriage of the C allele
created a putative NF-B binding site, we speculated that the
TLR9 1237 C allele would be associated with an increased
inflammatory state, which in our disease model meant in-
creased gastric damage characterized by the presence of HC
and gastric atrophy, the premalignant states of gastric cancer
seen in H. pylori-positive subjects.
Our findings showed that the C allele at TLR9 1237 was
associated with a significantly increased risk of HC and gastric
atrophy with an OR of 3.9 (95% CI  1.7 to 8.6). This finding
represents the second TLR polymorphism that our group has
shown to increase an individual’s risk of developing gastric
cancer. Previously TLR4 896G carriers were shown to have
an 11-fold (95% CI  2.5 to 48) increased OR of developing
gastric cancer (18). The association of the TLR4 896G poly-
morphism and also the TLR4 1196T polymorphism with in-
creased risk of gastric cancer have subsequently been assessed
in several studies, although their prevalence is known to vary
dramatically depending on the ethnic background (1, 32,
38, 41).
We subsequently assessed the functionality of the TLR9
1237 polymorphism for transcriptional activity and binding
affinity to NF-B. Our data suggest that TLR9 transcriptional
activity of the variant C allele is consistently higher than the
wild-type T allele when innate immunity pathways are acti-
vated. We also demonstrated that this increase in TLR9 tran-
scriptional activity is due to increased NF-B activation and
FIG. 4. Noshift assays using HeLa nuclear extracts were performed to assess the difference in binding affinity to NF-B between the two allelic
variant promoters, 46C and 46T, using HeLa nuclear extracts. Competition studies with unlabeled 46C (N46C), 46T (N46T), and standard
unlabeled NF-B competitor probes (SP) were performed. Unlabeled probes were added 10 times in excess compared to 46C by using the Student
t test (unpaired) (*, P  0.01). The figure shows the means 
 the SD of results obtained in three separate experiments.
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binding to the TLR9 promoter region when the C allele is
present.
Recently, data have been published examining the func-
tional activity of the TLR9 1237T/C SNP under basal condi-
tions, which showed that the T allele is transcribed more ef-
fectively than the C allele (29). Under similar experimental
conditions, i.e., basal, our findings are in concordance with
Novak et al. in that the wild-type construct elicits higher tran-
scriptional activity compared to the variant C allele. However,
unlike Novak et al., we did not observe a statistically significant
difference between constructs. Assuming that nuclear NF-B
concentrations are low prior to stimulation, assessing TLR9
basal transcriptional activity is a suboptimal approach to vali-
dating the functionality of this polymorphism in the context of
an infectious disease model such as our study. However, taking
the major differences of the etiology between allergic and in-
fectious disease models into the account, assessing basal tran-
scriptional activity of the allelic variants of the 1237T/C poly-
morphism may not be an inappropriate method in the atopic
eczema study. This may also help to explain the apparent
opposite association with risk alleles between atopic eczema
and infectious inflammatory diseases. Nevertheless, further
clarification is required to identify not only the competitiveness
of NF-B binding caused by the creation of an extra NF-B
binding site but also how the extra NF-B binding on the TLR9
promoter region of the C allele carriers leads to the formation
of a more effective transcriptional machinery. Previous studies
have suggested that H. pylori LPS is less potent than other LPS
preparations at inducing NF-B-dependent proinflammatory
cytokine production (26, 34, 42). In the present study, all LPS
preparations were ultrapurified to remove contaminating
lipoproteins to ensure activation was purely due to LPS. In the
luciferase studies, NF-B activation seen after H. pylori LPS
stimulation was between 30 and 50% lower than the Salmo-
nella LPS levels, suggesting the H. pylori LPS was capable but
not as effective at activating NF-B as Salmonella LPS, a find-
ing which is entirely consistent with the previous studies. Our
findings from the NF-B binding affinity study showed a non-
significant difference between Salmonella and H. pylori LPS.
One of the main questions relating to H. pylori gastric col-
onization is how the organism, which primarily resides within
the gastric lumen, is recognized by the immune system. It is
known that H. pylori can induce both humoral and cellular
immune responses, with several studies demonstrating that H.
pylori can invade gastric epithelial cells both in vitro (2) and in
vivo in the stomachs of humans and monkeys (33). H. pylori was
also shown to be in direct contact with immune cells of the
lamina propria in the majority of gastritis and gastric cancer
cases in a study by Necchi et al. (27). Dendritic cells, which
express a variety of TLRs, including TLR9, are an important
group of antigen-presenting cells within the gastric lamina pro-
pria. Once stimulated, dendritic cells influence the direction of
the immune response, and the stimulation of human dendritic
cells has been shown to respond directly to H. pylori bacteria
(12). H. pylori bacteria have also been shown to bind to the
dendritic cell receptor DC-specific ICAM-3-grabbing noninte-
grin (DC-SIGN) (3). Cytokine profiling of the gastric mucosa
suggests that both H. pylori infection and TLR9 activation
FIG. 5. 46C NF-B interaction analysis utilizing nuclear protein extracts obtained from HEK293 cells stimulated with TNF- (0.5 ng/ml for 20
min), S. Typhimurium and H. pylori LPS (both at 200 ng/ml for 30 min), and CpG-DNA (0.5 g/ml for 8.5 h). The percent increase in NF-B of
individual stimulation was calculated by normalizing to the negative, i.e., unstimulated, control. Binding activity is clearly observed between 46C
and HEK293 NF-B, and the amount of increase in NF-B nuclear translocation correlates with the increase in luciferase activity, i.e., the TLR9
promoter activity, shown earlier. The figure shows the means 
 the SD of results obtained in three separate experiments.
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induce a predominantly Th-1 immune response (4, 10). There-
fore, it is assumed that elevated TLR9 expression increases
host sensitivity to H. pylori CpG-DNA, which at least in part
enhances the Th-1 phenotype inflammatory effect seen during
the infection. TLR9 activation is known to stimulate IL-12/
IFN- production, which inhibits the expression of IgE recep-
tors on pDCs (20). This is partially responsible for the Th-1
phenotype suppressing Th-2 phenotype inflammation. Inter-
estingly, the TLR9 1237 “C” allelic variant, although shown
to increase TLR9 expression, has been shown to have no effect
on total serum IgE levels (5, 28). On this basis, we would have
anticipated that the TLR9 1237 “C” allele would continue to
be a risk factor for as long as the chronic inflammatory state
persists, i.e., at all stages of the H. pylori-induced gastric cancer
process. However, we have examined this possibility in two
large case control studies of gastric cancer based in Poland and
the United States, but we found no increased risk associated
with either study (17). It is clear, therefore, that this genetic
risk factor applies at the early stages of the neoplastic process.
Other factors assume more significance in the latter stages
which culminate in malignant transformation. The TLR9
1237 polymorphism may be relevant in setting the scene with
induction of severe inflammation, and this may allow other
factors to assume more significance later on. Having also pro-
vided evidence for the potential mechanisms by which this
effect occurs, it is now appropriate to assess the effect of the
polymorphism on other multistage infectious inflammatory
disease processes.
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